|本期目录/Table of Contents|

[1]饶 汕,陈 瑞,吕 晶.EGFR-TKI化疗后NSCLC肺叶切除术的疗效分析[J].中华肺部疾病杂志,2022,(05):700-702.[doi:10.3877/cma.j.issn.1674-6902.2022.05.022]
点击复制

EGFR-TKI化疗后NSCLC肺叶切除术的疗效分析(PDF)

《中华肺部疾病杂志》[ISSN:1006-6977/CN:61-1281/TN]

卷:
期数:
2022年05期
页码:
700-702
栏目:
临床研究
出版日期:
2022-10-20

文章信息/Info

Title:
-
作者:
饶 汕; 陈 瑞; 吕 晶
723000 汉中,汉中市中心医院胸外科
Author(s):
-
关键词:
非小细胞肺癌;  肺叶切除术;  表皮生长因子受体;  酪氨酸激酶抑制剂
Keywords:
-
分类号:
R563
DOI:
10.3877/cma.j.issn.1674-6902.2022.05.022
摘要:
目的 分析表皮生长因子受体-酪氨酸激酶抑制剂(EGFR-TKIs)靶向治疗非小细胞肺癌(NSCLC)后肺叶切除术的临床疗效。 方法 选择2017年3月至2019年2月我院经EGFR-TKI治疗的NSCLC患者117例为对象,其中接受肺叶切除术63例为观察组,未接受肺叶切除术54例为对照组。分析围手术期病死率,比较两组3年总生存期(OS)和无复发生存期(RFS)。Cox回归分析影响OS和RFS的因素。 结果 OS 观察组生存47例(74.60%)高于对照组23例(42.59%)(P<0.05); RFS 观察组未复发14例,对照组12例(22.22%)(P>0.05)。Cox回归分析术前CEA(HR=4.493)、EGFR-TKI治疗反应(PD)(HR=9.397)是肺叶切除术后影响OS的危险因素; EGFR-TKI化疗时年龄(≥70岁)(HR=12.597)、T分期(2～4)(HR=3.075)是肺叶切除术后影响RFS的危险因素(P<0.05)。 结论 EGFR-TKI靶向治疗NSCLC后肺叶切除术可延长OS,术前CEA、EGFR-TKI治疗反应(PD)、EGFR-TKI化疗年龄(≥70岁)及T分期(2～4)影响肺叶切除术预后。
Abstract:
-

参考文献/References:

1 Ahn MJ, Sun JM, Lee SH, et al. EGFR TKI combination with immunotherapy in non-small cell lung cancer[J]. Expert Opin Drug Saf, 2017, 16(4): 465-469.
2 杨 玖, 洪 梅, 刘志远, 等. 放疗联合EGFR-TKI靶向治疗对Ⅳ期非小细胞肺癌患者血清肿瘤标记物及疗效的影响[J]. 河北医学, 2020, 26(1): 4-8.
3 王 旭, 袁五营, 徐文举. 非小细胞肺癌中EGFR突变与EGFR-TKI临床敏感性及耐药性之间的相关性研究[J]. 成都医学院学报, 2020, 15(2): 227-231.
4 韩 昕, 白维君. EGFR-TKI靶向治疗EGFR19或21突变的非小细胞肺癌临床分析[J]. 肿瘤学杂志, 2020, 26(1): 71-74.
5 Isomoto K, Haratani K, Hayashi H, et al. Impact of EGFR-TKI treatment on the tumor immune microenvironment in EGFR mutation-positive non-small cell lung cancer[J]. Clin Cancer Res, 2020, 26(8): 2037-2046.
6 郑慧禹, 邵志鹏, 赵冬峰, 等. 胸腔镜微创手术与传统开胸手术治疗非小细胞肺癌患者的临床疗效比较[J]. 癌症进展, 2021, 19(5): 499-502,506.
7 Rotow J, Bivona TG. Understanding and targeting resistance mechanisms in NSCLC[J]. Nat Rev Cancer, 2017, 17(11): 637-658.
8 Hishida T, Yoshida J, Aokage K, et al. Long-term outcome of surgical resection for residual or regrown advanced non-small cell lung carcinomas following EGFR-TKI treatment: report of four cases[J]. Gen Thorac Cardiovasc Surg, 2016, 64(7): 429-33.
9 Gomez DR, Tang C, Zhang J, et al. Local consolidative therapy vs. Maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer: Long-term results of a multi-institutional, Phase Ⅱ, randomized study[J]. J Clin Oncol, 2019, 37(18): 1558-1565.
10 支修益, 石远凯, 于金明. 中国原发性肺癌诊疗规范(2015年版)[J]. 中华肿瘤杂志, 2015, 37(1): 67-78.
11 Schwartz LH, Litière S, de Vries E, et al. RECIST 1.1-Update and clarification: From the RECIST committee[J]. Eur J Cancer, 2016, 62(1): 132-137.
12 Kawakami Y, Ogura S. [The outline of the general rule for clinical and pathological record of lung cancer][J]. Nihon Rinsho, 2000, 58(5): 999-1004.
13 蔡 颖. FLT3-ITD突变高等位基因比率在急性髓系白血病中的预后意义[D]. 江苏:苏州大学,2020:78-92.
14 李鹏飞, 赖玉田, 周坤,等. 应用Clavien-Dindo分级系统对肺癌患者术后并发症分级及危险因素分析[J]. 中国肺癌杂志, 2017, 20(4):264-271.
15 石辉兵. 非小细胞肺癌患者EGFR-TKI靶向治疗前后肿瘤r体积变化规律及其临床价值分析[J]. 医药前沿, 2018, 8(19):104.
16 Yoneda K, Imanishi N, Ichiki Y, et al. Treatment of non-small cell lung cancer with EGFR-mutations[J]. J UOEH, 2019,41(2):153-163.
17 Lin A, Wei T, Meng H, et al. Role of the dynamic tumor microenvironment in controversies regarding immune checkpoint inhibitors for the treatment of non-small cell lung cancer(NSCLC)with EGFR mutations[J]. Mol Cancer, 2019,18(1): 139.
18 Gelatti ACZ, Drilon A, Santini FC. Optimizing the sequencing of tyrosine kinase inhibitors(TKIs)in epidermal growth factor receptor(EGFR)mutation-positive non-small cell lung cancer(NSCLC)[J]. Lung Cancer, 2019, 137(1): 113-122.
19 Ohtaki Y, Shimizu K, Suzuki H, et al. Salvage surgery for non-small cell lung cancer after tyrosine kinase inhibitor treatment[J]. Lung Cancer, 2021, 153(1): 108-116.
20 Ning Y, Bao M, Yan X, et al. Surgery for advanced non-small cell lung cancer patient after epidermal growth factor receptor tyrosine kinase inhibitor neoadjuvant therapy[J]. Ann Transl Med, 2018, 6(20): 407.
21 Chen K, Cheng G, Zhang F, et al. PD-L1 expression and T cells infiltration in patients with uncommon EGFR-mutant non-small cell lung cancer and the response to immunotherapy[J]. Lung Cancer, 2020, 142(1): 98-105.
22 Yamamoto Y, Kodama K, Maniwa T, et al. Surgical resection of advanced non-small cell lung cancer after a response to EGFR-TKI: presentation of two cases and a literature review[J]. J Cardiothorac Surg, 2017, 12(1): 98.
23 Hamada A, Soh J, Mitsudomi T. Salvage surgery after definitive chemoradiotherapy for patients with non-small cell lung cancer[J]. Transl Lung Cancer Res, 2021, 10(1): 555-562.
24 Koizumi T, Aoki T, Saito M, et al. Salvage surgery to treat tumor regrowth after stereotactic body radiotherapy in primary non-small cell lung cancer[J]. J Thorac Dis, 2020, 12(10): 5289-5298.
25 Horio Y, Mizuno T, Sakao Y, et al. Successful salvage surgery following multimodal therapy in a patient who harboured ALK-rearranged advanced lung adenocarcinoma with multiple organ metastases[J]. Respirol Case Rep, 2019, 7(7): e00451.
26 Garon EB, Hellmann MD, Rizvi NA, et al. Five-year overall survival for patients with advanced non-small-cell lung cancer treated with pembrolizumab: Results from the phase I KEYNOTE-001 Study[J]. J Clin Oncol, 2019, 37(28): 2518-2527.
27 Le X, Negrao MV, Reuben A, et al. Characterization of the immune landscape of EGFR-Mutant NSCLC Identifies CD73/adenosine pathway as a potential therapeutic target[J]. J Thorac Oncol, 2021, 16(4): 583-600.
28 Fang Y, Wang Y, Zeng D, et al. Comprehensive analyses reveal TKI-induced remodeling of the tumor immune microenvironment in EGFR/ALK-positive non-small-cell lung cancer[J]. Oncoimmunology, 2021, 10(1): 1951019.
29 陈雯微. 血清CEA、CA125及Cyfra21-1水平与中晚期非小细胞肺癌患者的临床特征与预后相关性分析[J]. 中国医师杂志, 2019, 21(11): 1714-1716.
30 张海涛, 王 春, 张映铭, 等. 非小细胞肺癌患者EGFR突变率及与临床病理关系和TKI靶向治疗效果[J/CD]. 中华肺部疾病杂志(电子版), 2019, 12(2): 175-180.

备注/Memo

备注/Memo:
基金项目: 陕西省重点研发计划项目(2019SF-148)
通信作者: 吕 晶, Email: 314048815@qq.com
更新日期/Last Update: 2022-10-20